Cynosure obtained FDA clearance for the PicoSure system to treat acne scars.
I noted in my original article that Cynosure launched PicoSure in the U.S. for tattoo removal, although I didn’t anticipate that it would be approved for acne scars.
I said that the company’s PicoSure and PrecisionTx will drive significant revenues; PicoSure approval confirms my view.
Cynosure (NASDAQ:CYNO) bagged FDA clearance for the PicoSure system to treat acne scars few days ago. For removing acne scars, the PicoSure system uses short bursts of laser energy to dissolve the scars into smaller particles that are eliminated by the body. PicoSure is also used to remove tattoos and benign pigmented lesions safely and effectively using the company's Focus disposable lens array technology. The greatest advantage of the device is that it works without leaving any adverse impact on the skin.
PicoSure scored superior results in clinical studies with 77% of patients treated with PicoSure having more than 50% improvement in scar treatment as rated by physicians. Furthermore, the device has a patient satisfaction rating of 76% at one-month follow up and 86% at three-month follow up.
In my original article, I said that unlike competitive technologies, such as Syneron's (NASDAQ:ELOS) AlexTriVantage that uses nanosecond lasers, the picosecond laser emitted by PicoSure does not rely on delivering thermal energy to the tissue to heal scars. Cynosure has tremendous opportunities in laser skin resurfacing, laser hair and tattoo removal and laser body contouring.